drugset

drugset / Trial / NCT00323817

To Evaluate the Efficacy and Safety in Subjects With Functional Dyspepsia

NCT00323817 ↗

Phase 2 Completed 282 enrolled Zeria Pharmaceutical

RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the efficacy and safety of Z-338 in subjects with Functional Dyspepsia

Timeline

Start: 2006-04
Primary completion: 2009-04
Completion: 2009-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Acotiamide	Small molecule	—	—

Indications